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Background: Neoadjuvant radiochemotherapy has proven superior to adjuvant treatment in reducing the rate of
local recurrence without impairing cancer related survival or the incidence of distant metastases. The present study
aimed at addressing the effects of an intensified protocol of neoadjuvant treatment on the development of
postoperative complications.
Methods: A total of 387 patients underwent oncological resection for rectal cancer in our institution between
January 2000 and December 2009. 106 patients received an intensified radiochemotherapy. Perioperative morbidity
and mortality were analyzed retrospectively with special attention on complication rates after intensified radio-
chemotherapy. Therefore, for each patient subjected to neoadjuvant treatment a patient without neoadjuvant
treatment was matched in the following order for tumor height, discontinuous resection/exstirpation, T-category of
the TNM-system, dividing stoma and UICC stage.
Results: Of all patients operated for rectal cancer, 27.4% received an intensified neoadjuvant treatment. Tumor location
in the matched patients were in the lower third (55.2%), middle third (41.0%) and upper third (3.8%) of the rectum.
Postoperatively, surgical morbidity was higher after intensified neoadjuvant treatment. In the subgroup with low anterior
resection (LAR) the anastomosis leakage rate was higher (26.6% vs. 9.7%) and in the subgroup of patients with rectal
exstirpations the perineal wound infection rate was increased (42.2% vs. 18.8%) after intensified radiochemotherapy.
Conclusions: In rectal cancer the decision for an intensified neoadjuvant treatment comes along with an increase of
anastomotic leakage and perineal wound infection. Quality of life is often reduced considerably and has to be
balanced against the potential benefit of intensifying neoadjuvant radiochemotherapy.
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For advanced rectal cancer, neoadjuvant radiochemother-
apy has been proven to reduce the rate of local recurrence
in comparison to postoperative treatment [1]. German
guidelines state exact treatment rules for UICC stage I
to III and localization of cancer in the rectum [2]. The
decision for a neoadjuvant treatment is based on local
staging. Since there has been no impact of neoadjuvant
treatment on cancer related survival or distant metastases
[1], effort was taken to improve the systemic results of
the neoadjuvant radiochemotherapy (RCT). By adding a* Correspondence: leif.Schiffmann@med.uni-rostock.de
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distribution, and reproduction in any mediumsecond drug to the neoadjuvant radiochemotherapy, the
rate of complete responses and tumor regression grade
could be increased [3-5]. A complete response has been
shown to be a predictive marker for disease free and
cancer related survival. Thus, an intensified neoadjuvant
RCT protocol was introduced at several institutions
including irinotecan or oxaliplatin [5-15].
A potential increase of perioperative morbidity following
an intensified radiochemotherapy has not been reported
so far [4,5].
The aim of this study was to investigate, whether an
intensified neoadjuvant radiochemotherapy leads to an
increase of perioperative surgical morbidity.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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All patients treated for rectal cancer with an oncological
resection in our institution between January 2000 and
December 2009 were included into this retrospective
study after identification by the pathological data base. The
term rectum carcinoma was applied to adenocacinomas
located at a distance from 0 to 16 cm from the anal verge
measured by rectoscopy. The cancer was located in either
the lower (0- < 6 cm), middle (6- < 12 cm) or upper
(12-16 cm) rectum. Patients’ records were analyzed
under special consideration of neoadjuvant treatment,
type of operation and perioperative complications.
According to German guidelines, there was an indication
for neoadjuvant RCT for T3, T4 and /or nodal positive
tumors of the lower and middle third of the rectum. In
the upper third of the rectum, the only indication for
neoadjuvant treatment was a T4 cancer. In our facility,
the majority of neoadjuvant treated patients received an
intensified neoadjuvant radiochemotherapy, which changed
within the observation period. From January 2000 to
January 2002 patients received a combination of a continu-
ous infusion 5-FU (250 mg/m2 per day) over 31 days, seven
weekly applications of irinotecan (40 mg/m2) and a local
radiation five days a week with a single dose of 1.8 Gy
adding up to 50.4 Gy (last three doses were reduced). From
February 2002 5-FU was substituted by a daily intake of
Capecitabine with a single dose between 1000 and
1650 mg/m2. Doses of radiation were no longer reduced
and reached a cumulative dose of 55.8 Gy. Oxaliplatin had
been applied instead of Irinotecan in eight patients.387 pat
excluded:
29 patients: other malignancy
10 patients: short term radiation
16 patients: conventional neoadj
8 patients: inRCT not complete






decreasing preference by tumor height,
T-category of the TNM-system, d
Figure 1 This flow chart shows the matching of the patients and theThe type of surgery depended on localization of the
tumor, preoperative stool incontinence and general
condition of the patient. Generally, patients received a
total mesorectal excision (TME) for all cancers located
between 0 and 12 cm and a partial mesorectal excision
(PME) for all cancers located higher than 12 cm. All
anastomoses were performed by double stapling tech-
nique. Postoperatively, in case of unusual elevation of CRP
or white blood cell count, clinical symptoms as well as
suspicious drain secretion, diagnostics were performed
to determine an anastomotic leakage by rectal digital
examination, water soluble contrast study, endoscopy or
ct-scan. If any of the diagnostic tools showed an anasto-
motic leakage it was documented as such regardless of the
clinical consequences (stage I-III).
After identifying all patients with a rectal adenocarcin-
oma, we eliminated all patients receiving a short term
radiation (5×5 Gy), conventional neoadjuvant radiochemo-
therapy and all patients having complications during the
intensified neoadjuvant treatment (11 patients) or having
another malignancy in their history (5 patients). There-
after, the study population was divided into patients with
intensified neoadjuvant RCT and without any neoadjuvant
treatment. There were 106 patients eligible to the intensi-
fied neoadjuvant RCT group. After that, 106 patients of the
not neoadjuvant treated group were matched in decreasing
preference by tumor height, discontinuous resection/
exstirpation, T-category of the TNM-system, diverting
stoma and UICC stage (Figure 1). Of these 106 patients,








 discontinuous resection/exstirpation, 
iverting stoma and UICC stage
106 patients
reasons of exclusions from the study.
Table 1 Patient and cancer characteristics for patients











Gender ratio (f : m) 1 : 2.92 1 : 1.35 0.01
Age 62.3 68.5 0.067
Comorbidity 68.6 84.6 0.009
Pulmonary 5.7 14.4 0.041
Cardiovascular 21.9 25.0 0.627
Renal 6.7 11.5 0.239
Diabetes 11.4 19.2 0.128
Hypertension 40.0 56.7 0.019
Others 39.0 62.5 0.001
ASA score (mean) 2.28 2.38 0.228




Discontinous resection 38.7 40.6 0.888




Infiltration of anal sphincter
(discontinous resections only)
54.2 47.8 0.773













Number of nodes examined 15.3 18.8 0.001
UICC stage 0.116
UICC 0 3.8 0.0
UICC I 24.5 32.1
UICC II 17.0 17.0
UICC III 31.1 35.8
UICC IV 23.6 15.1
Localization 0.986
Upper Rectum 3.8 3.8
Middle Rectum 40.4 41.5
Lower rectum 55.8 54.7
Tumorheight (cm) 5.26 5.31 0.199
Patient characteristics were recorded within three days before surgery, tumor
heights was documented at the time of staging and cancer characteristics
were taken from the pathological report.
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Irinotecan and 50.4 Gy; 20 patients received a combination
of 5FU, Irinotecan and 55.8 Gy; 42 patients received a
combination of Capecitabine, Irinotecan and 55.8 Gy; 8
patients received a combination of 5FU, Oxaliplatin
and 50.4 Gy.
The study was approved by the Medical Ethical Com-
mittee of Rostock University.
Statistical analysis
Statistical analysis was performed using Statistical Package
for Social Science (SPSS) version 15.0. Statistical analysis
was done using Pearson’s chi-square test or Fisher’s exact
test.
Results
Between January 2000 and December 2009 387 patients
were operated for rectal cancer. In this cohort 106 patients
were identified who received an intensified neoadjuvant
RCT. These patients were matched with 106 patients,
who did not receive any neoadjuvant treatment, for tumor
height, discontinuous resection/exstirpation, T-category of
the TNM-system, diverting stoma and UICC stage. To
rule out, that only the good cases were matched from the
not neoadjuvantly treated group, we analyzed the not
neoadjuvantly treated group in terms of matched and
not matched patients. The main differences were, that
the not matched patients had a higher tumor localization
and a more frequent operative revision.
Table 1 shows the matching results. As expected, the
number of evaluated lymph nodes was higher in patients
without neoadjuvant treatment.
Table 2 shows the complications of the two groups.
There were no differences in mortality and overall compli-
cations. Non surgical complications were higher in the not
neoadjuvant treated group. Surgical complications were
significantly different. The anastomosis leakage rate was 3
fold higher in the neoadjuvantly treated group. There was
a difference in leakage rate between men and women in
the study-group (16.1%) and within the control group
(13.5%), which did not reach statistical significance. The
perineal wound infection rate in patients with a rectum
exstirpation was more than 2-fold, the revision rate
was more than 3-fold higher after neoadjuvant RCT.
The overall surgical morbidity is also significantly higher
after neoadjuvant RCT.
Discussion
We retrospectively analyzed the postoperative course
of patients with rectal cancer subjected to intensified
neoadjuvant RCT in comparison with patients who were
not treated before surgery. The question was, whether pa-
tients treated before surgery had a higher rate of morbidity
and mortality compared with the group that did not











30 day mortality 0.0 1.9 0.244
Complications 53.8 50.5 0.550
Non surgical 11.3 23.1 0.028
Urinary infection 2.8 9.6 0.048
Pneumonia 3.8 6.7 0.371
Cardiopulmonary events 0.9 4.8 0.117










Operative revision (LAR only) 20.3 6.5 0.035
After administrating intensified neoadjuvant treatment, there is no increase in
non surgical morbidity, but a severe increase in surgical morbidity like
anastomosis leakage or wound infections.
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study is that intensified neoadjuvant radiochemotherapy
resulted in a significantly higher surgical morbidity rate.
To rule out known risk factors, this study was designed as
matched pair analysis with matching patients 1 to 1 in
decreasing priority for tumor height, discontinuous resec-
tion, tumor infiltration, dividing stoma and UICC stage.
Patients in the neoadjuvantly treated group were younger




Own results (n = 212) +/− intensified RCT 0
Sauer et al. [1] (n = 823) Pre/post-operative RCT 0
Bosset et al. [20] (n = 1011) RT/RCT 1
Kapiteijn et al. [19] (n = 1861) +/− RT No d
Voelter et al. [8] (n = 33) Intensified RCT
Horisberger et al. [21] (n = 59) All patients / major/minor
response to intensified RCT
6
Gollins et al. [14] (n = 46) Intensified RCT
Aschele et al. [22] (n = 747) Intensified (Oxaliplatin)/“not
intensified” RCT
Sato et al. [23] (n = 67) S-1 plus Irinotecan
Garlipp et al. [24] (n = 2085) +/− preoperative chemoradio-therapy
Fucini et al. [25] (n = 80) +/− preoperative RCT
+delayed healing, §wound dehiscence, &other complication/undetermined.ASA score. The number of examined lymph nodes was
lower after intensified neoadjuvant RCT complying with
previous reports [16]. Some patients had a total reduction
of the tumor and had therefore an ypT0 and/or UICC 0
classification. In conclusion, matching was successful and
the groups were comparable.
Patients without neoadjuvant RCT were older and had a
higher rate of comorbidities. This propably was the reason
for an increased non-surgical morbidity. The group with-
out neoadjuvant treatment had a leakage rate of 9.7% and
was comparable with the results of other institutions
[17,18]. But nevertheless the overall surgical morbidity
after intensified neoadjuvant treatment (especially anas-
tomotic leakage of 26.6% and perineal wound infection
rate of 42.2%) in our series is rather high compared to
other groups as shown in Table 3 ranging between 0%
and 25.9%. The quality of surgery appears to be compa-
rable with other groups represented by the number of
lymph nodes harvested [19]. Other groups reported that
there was no increase of surgical morbidity after apply-
ing non-intensified neoadjuvant radiochemotherapy
(Table 3) [1,20]. By adding an extra agent, surgical re-
sults seem to be influenced in a negative way [21]. If
there was a benefit in oncologic outcome and if this
potential benefit would compensate the increased sur-
gical morbidity, it remains yet uncertain.
Taking the literature into account as shown in Table 3,
the intensivation of neoadjuvant RCT according to
Horisberger et al. [21] appears to be even more aggressive
compared to a neoadjuvant treatment without intensivation
[1,24] and results in a higher surgical complication rate.
On the other hand, Gollins et al. [14], Aschele et al. [22],









/ 1.9 26.6 / 9.7 20.3 / 6.5 42.2 / 18.8
.7 / 1.3 11 / 12 10 / 8+
.2 / 2.4
ifference No difference 26 / 18
3 6 58
3.4 15.5 15.5
.1 / 0 25.9 / 0 25.9 /0
0 6.4 22.2§
1 / 1 2 / 1 9 / 9&
0 0 0 0
12.4 / 12.7 5.5 / 7.5
2 / 0 14.8 / 9.1
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respectively from a group of 31, 747, 67 and 21 patients
with sphincter sparing surgery. All studies concerning an
intensified neoadjuvant RCT regime lack either a substan-
tial number of patients and are basically series without a
control group or do not focus on the surgical outcome
[5,15,22,23]. So far, there has been no explanation, how
an additional chemotherapeutic agent could influence
surgical morbidity of a subsequent operation which usually
takes place 6 weeks after termination of radiochemothe-
rapy. Horisberger et al. [21] found a relationship between
tumor response to intensified neoadjuvant therapy and
major complications. The rate of anastomotic leakages was
25.9% in the group with a major response comparing to
0% in the group with a minor response to the neoadjuvant
treatment. The authors suggest that collagen deposition,
the depressing effect on the blood cells and other essential
elements of wound healing as well as different definitions
of anastomotic dehiscence and the irritation of bowel
mucosa could have influenced this result. While the
large multicenter studies on the oncological impact of
radio(chemo)therapy [1,19,20] do not show differences
in the anastomotic leakage rate with or without pre- or
postoperative radio-(chemo)-therapy, we demonstrate in
our study the results of a single center institution with a
standardized and reproducible treatment concept surgi-
cally as well as perioperatively. It should be pointed out,
that surgical morbidity and mortality was not the main
focus of the studies mentioned above whereas surgical
complications were the main aim of our investigation.
However, in a retrospective multicenter study Garlipp
et al. [24] focused on the effect of neoadjuvant radioche-
motherapy on the anastomotic leak rate and did not find
any differences between groups, even though the tumor
location was significantly lower in patients subjected to
neoadjuvant treatment. Weiss et al. [5] report pooled data
from three trials administering neoadjuvant RCT with
capecitabine and oxaliplatin with or without cetuximab.
The leakage rate is reported to be 11 per cent of all in-
cluded patients without stating the fractions of patients
with anterior resection or exstirpation of the rectum.
Gerard et al. [15] report low anastomotic leakage rates
of 6.2% (12 out of 195 patients) administering only
capecitabine and 4,9% (10 out of 205 patients) using
capecitabine and oxaliplatin in the neoadjuvant RCT
regime. Aschele et al. [22] and Sato et al. [23] report
extremely low anastomotic leakage rates of 2% and 0%.
This is noteworthy since the generally accepted leakage
rate after rectal resection reported from leading surgical
departments ranges from 5.5% to 37.5% [1,24-32]. Also,
a recent study showed a threefold higher anastomotic
leakage rate in males in comparison to females after
laparoscopic rectal resections [33]. This correlation
was somewhat debatable in the past [32]. In our study,there was also a difference between males and females,
but due to smaller patient numbers, we did not reach
significant differences.
There are only few studies addressing perineal wound
infection rate after neoadjuvant treatment in the literature.
Data from Gollins et al. [14] as well as Voelter et al. [8]
show a higher rate of perineal wound infections after
an intensified regime (22.2 and 58%) compared with
10% and 26% after conventional preoperative radioche-
motherapy [1,19]. Our study confirms a high incidence of
perineal wound infection following intensified neoadjuvant
radiochemotherapy.
Conclusions
In conclusion intensified neoadjuvant radiochemotherapy
in rectal cancer patients resulted in a higher surgical com-
plication rate compared with patients without neoadjuvant
RCT in our institution as demonstrated by this retrospec-
tive matched pair analysis. Our results are in accordance
with previous studies in the literature concerning a high
rate of perineal wound infections after rectal exstirpation,
but not with respect to the demonstrated increase of
anastomotic breakdown following resection. However,
most of these studies have the draw-back that surgical
complications were not the main focus and therefore
the key parameters were not analyzed in detail. Further
studies are required to substantiate our findings and
to investigate whether an increase in surgical complication
rate is warranted by a significant improvement of onco-
logical outcome.
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